Novartis announced it will discontinue the trial for organ rejection in patients receiving a kidney transplant.
The analysis indicated that CF Z533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant.
Both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy, mycophenolate and corticosteroids). Study of CFZ533 in liver transplant continues, as do studies exploring CFZ 533 as a potential treatment in other conditions, such as hidradenitis suppurativa and Sjögren’s syndrome. Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, results will be shared with the broader scientific community.
Related news and insights
argenx a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive.
Telix Pharmaceuticals announces that the FDA has approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.
Regeneron Pharmaceuticals, Inc.and Sanofi announced that the European Commission (EC) has approved Dupixent (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy . With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.